DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for complement component 3 deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleComplement component 3 deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for complement component 3 deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
complement C3 (C3) — C3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9U62 · 2.7 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Complement component 3 deficiency is a rare inherited state in which the C3 protein, the convergence point of the classical and alternative complement pathways, is absent or non-functional. The abstracts provided are reviews, not original clinical trials, so no patient outcomes from a treated cohort are available. The 1991 review states that complement deficiency states are associated with predictable defects in complement-dependent functions and are most prevalent in patients with certain rheumatologic and infectious diseases. It notes that complement appears most important in protection against encapsulated bacteria, especially Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and, to a lesser extent, Neisseria gonorrhoeae. The same review recommends the use of effective polysaccharide vaccines and antibiotics for preventing and treating infection in patients with these deficiencies, but no data on survival or response rates in C3-deficient patients are given.
A 2018 review on serological complement biomarkers states that complement system aberrations have been identified in infections, inflammation, autoimmune disease, and transplantation. It reports that prospective and retrospective studies have shown significant complement-related differences between patient groups and controls, but that due to low specificity and sensitivity of some assays, predictions about individual patients are not always possible. A 2023 review similarly discusses complement deficiency states and consumption of complement by immune-complex diseases, but provides no specific numbers for C3 deficiency. A 2012 review repeats that deficiency of complement components or regulators can lead to life-threatening conditions and explains the rationale behind complement-targeted therapies, again without original data on C3 deficiency.
No abstract reports a clinical trial testing a drug specifically for complement component 3 deficiency. The only therapeutic strategies mentioned are vaccination and antibiotics, which are general measures for infection risk rather than treatments for the deficiency itself. What is still missing is any dedicated clinical trial, any patient stratification by residual complement function, and any funding for a drug-repurposing study in this ultra-rare population. Without such data, the clinical course of C3 deficiency remains defined only by infection susceptibility and the absence of evidence for any pharmacological intervention beyond standard prophylaxis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Infectious diseases associated with complement deficiencies
AbstractThe complement system consists of both plasma and membrane proteins. The former influence the inflammatory response, immune modulation, and host defense. The latter are complement receptors, which mediate the cellular effects of complement activation, and regulatory proteins, which protect host cells from complement-mediated injury. Complement activation occurs via either the classical or the alternative pathway, which converge at the level of C3 and share a sequence of terminal components. Four aspects of the complement cascade are critical to its function and regulation: (i) activation of the classical pathway, (ii) activation of the alternative pathway, (iii) C3 convertase formation and C3 deposition, and (iv) membrane attack complex assembly and insertion. In general, mechanisms evolved by pathogenic microbes to resist the effects of complement are targeted to these four steps. Because individual complement proteins subserve unique functional activities and are activated in a sequential manner, complement deficiency states are associated with predictable defects in complement-dependent functions. These deficiency states can be grouped by which of the above four mechanisms they disrupt. They are distinguished by unique epidemiologic, clinical, and microbiologic features and are most prevalent in patients with certain rheumatologic and infectious diseases. Ethnic background and the incidence of infection are important cofactors determining this prevalence. Although complement undoubtedly plays a role in host defense against many microbial pathogens, it appears most important in protection against encapsulated bacteria, especially Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and, to a lesser extent, Neisseria gonorrhoeae. The availability of effective polysaccharide vaccines and antibiotics provides an immunologic and chemotherapeutic rationale for preventing and treating infection in patients with these deficiencies.
New England Journal of Medicine · 1987 · 138 citations
Familial Properdin Deficiency and Fatal Meningococcemia
AbstractINHERITED deficiencies of various complement proteins are being recognized with increasing frequency. Careful evaluation of these deficiency states has augmented our understanding of the biologic function of individual components of the complement system, as well as of the system as a whole. Approximately half the affected persons are healthy. Nevertheless, typical clinical features have been found in the remainder, and should suggest a diagnosis of complement deficiency and identify the particular component or activation pathway that is defective.1 , 2 Inherited deficiencies of the nonregulatory components of the alternative pathway have been recognized only rarely. This report describes a large family in . . .
Frontiers in Immunology · 2018 · 118 citations · open access
Interpretation of Serological Complement Biomarkers in Disease
AbstractComplement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders.
AbstractThe role of complement in human autoimmune, inflammatory, and infectious diseases is reviewed, focusing on clinical applicability. A typical case is presented in which serum testing for C3 and C4 is performed to help assess a syndrome with a broad differential diagnosis. The review includes a discussion of complement deficiency states, consumption of complement by diseases characterized by immune-complex formation and deposition, usefulness and interpretation of laboratory tests for complement, and development of drugs targeting specific components of the complement pathway for a growing number of indications.
Infectious diseases associated with complement deficiencies.
AbstractThe complement system consists of both plasma and membrane proteins. The former influence the inflammatory response, immune modulation, and host defense. The latter are complement receptors, which mediate the cellular effects of complement activation, and regulatory proteins, which protect host cells from complement-mediated injury. Complement activation occurs via either the classical or the alternative pathway, which converge at the level of C3 and share a sequence of terminal components. Four aspects of the complement cascade are critical to its function and regulation: (i) activation of the classical pathway, (ii) activation of the alternative pathway, (iii) C3 convertase formation and C3 deposition, and (iv) membrane attack complex assembly and insertion. In general, mechanisms evolved by pathogenic microbes to resist the effects of complement are targeted to these four steps. Because individual complement proteins subserve unique functional activities and are activated in a sequential manner, complement deficiency states are associated with predictable defects in complement-dependent functions. These deficiency states can be grouped by which of the above four mechanisms they disrupt. They are distinguished by unique epidemiologic, clinical, and microbiologic features and are most prevalent in patients with certain rheumatologic and infectious diseases. Ethnic background and the incidence of infection are important cofactors determining this prevalence. Although complement undoubtedly plays a role in host defense against many microbial pathogens, it appears most important in protection against encapsulated bacteria, especially Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and, to a lesser extent, Neisseria gonorrhoeae. The availability of effective polysaccharide vaccines and antibiotics provides an immunologic and chemotherapeutic rationale for preventing and treating infection in patients with these deficiencies.
LaboratoriumsMedizin · 2012 · 5 citations · open access
Modern complement analysis: indications, methods and outlook1),2)
AbstractAbstract Complement is one of the key systems of innate immunity and homeostasis. Its excessive activation and also a deficiency of complement components or regulators can lead to life-threatening conditions. This review aims to provide the basic knowledge that clinicians need in order to understand complement-related diseases. Moreover, it shows possible indications and interpretations of a complement analysis and explains the rationale behind complement-targeted therapies.
Modern complement analysis: indications, methods and outlook<sup>1),2)</sup>
AbstractAbstract Complement is one of the key systems of innate immunity and homeostasis. Its excessive activation and also a deficiency of complement components or regulators can lead to life-threatening conditions. This review aims to provide the basic knowledge that clinicians need in order to understand complement-related diseases. Moreover, it shows possible indications and interpretations of a complement analysis and explains the rationale behind complement-targeted therapies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
